What do systematic reviews say?

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

ADHD symptoms · people with ADHD and epilepsy

50% or greater reduction in seizure frequency · people with ADHD and epilepsy

Seizure severity · people with ADHD and epilepsy

Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis

Exacerbation frequency · people with bronchiectasis

Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis

Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis

Total costs per QALY · people with bilateral age‐related cataracts (NRSs)

BCDVA · people with bilateral age‐related cataracts (NRSs)

Patient‐reported outcome measures (PROMs) · people with bilateral age‐related cataracts (NRSs)

Quality of life: change from baseline in CFQ‐R · children and young adults with CF

Participant preference · children and young adults with CF

Need for extra antibiotics (days) · children and young adults with CF

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

Change in VO2 peak during maximal exercise · adults and children with cystic fibrosis

Quality of life: change from baseline in CFQ‐R · adults and children with cystic fibrosis